Clinical trials
Phase 1 Biliary Tract Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 3 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 13 |
| Completed | 10 |
| Terminated | 4 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 2 |
| SystImmune Inc. | 2 |
| University of California, San Francisco | 2 |
| AbGenomics B.V Taiwan Branch | 1 |
| Array Biopharma, now a wholly owned subsidiary of Pfizer | 1 |
| AstraZeneca | 1 |
| Black Diamond Therapeutics, Inc. | 1 |
| Carisma Therapeutics Inc | 1 |
| Eli Lilly and Company | 1 |
| Fujifilm Pharmaceuticals U.S.A., Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biliary Tract Neoplasms | 34 |
| Stomach Neoplasms | 13 |
| Colorectal Neoplasms | 12 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Endometrial Neoplasms | 9 |
| Breast Neoplasms | 8 |
| Pancreatic Neoplasms | 8 |
| Carcinoma, Hepatocellular | 6 |
| Cholangiocarcinoma | 6 |
| Ovarian Neoplasms | 6 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.